Allogene prices IPO at top of range

|About: Allogene Therapeutics (ALLO)|By:, SA News Editor

Clinical-state biotech Allogene Therapeutics (ALLO) has priced its initial public offering at the top of its range, IPO Boutique says.

The company priced 16M shares at $18 each.

That's the top of a marketed range of $16-$18 each, making for a raise of $288M.

The company is run by biotech veterans Arie Belldegrun and David C. Chang.

It's set to debut tomorrow on Nasdaq Global Select Market.

Previously: Allogene sets terms of IPO (Oct. 02 2018)

Previously: Allogene Therapeutics readies IPO (Sep. 14 2018)

Subscribe for full text news in your inbox